CA2869899A1 - Nouvelle proteine interferon-.lambda.4 (ifnl4), molecules d'acide nucleique associees, et leurs utilisations - Google Patents

Nouvelle proteine interferon-.lambda.4 (ifnl4), molecules d'acide nucleique associees, et leurs utilisations Download PDF

Info

Publication number
CA2869899A1
CA2869899A1 CA2869899A CA2869899A CA2869899A1 CA 2869899 A1 CA2869899 A1 CA 2869899A1 CA 2869899 A CA2869899 A CA 2869899A CA 2869899 A CA2869899 A CA 2869899A CA 2869899 A1 CA2869899 A1 CA 2869899A1
Authority
CA
Canada
Prior art keywords
seq
ifnl4
protein
position corresponding
residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2869899A
Other languages
English (en)
Other versions
CA2869899C (fr
Inventor
Liudmila PROKUNINA
Thomas R. O'brien
Brian MUCHMORE
Raymond P. DONNELLY
Patricia A. PORTER-GILL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of CA2869899A1 publication Critical patent/CA2869899A1/fr
Application granted granted Critical
Publication of CA2869899C publication Critical patent/CA2869899C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA2869899A 2012-03-28 2013-03-14 Nouvelle proteine interferon-.lambda.4 (ifnl4), molecules d'acide nucleique associees, et leurs utilisations Active CA2869899C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261616664P 2012-03-28 2012-03-28
US61/616,664 2012-03-28
PCT/US2013/031624 WO2013148272A1 (fr) 2012-03-28 2013-03-14 Nouvelle protéine interféron-λ4 (ifnl4), molécules d'acide nucléique associées, et leurs utilisations

Publications (2)

Publication Number Publication Date
CA2869899A1 true CA2869899A1 (fr) 2013-10-03
CA2869899C CA2869899C (fr) 2021-06-22

Family

ID=47998550

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2869899A Active CA2869899C (fr) 2012-03-28 2013-03-14 Nouvelle proteine interferon-.lambda.4 (ifnl4), molecules d'acide nucleique associees, et leurs utilisations

Country Status (8)

Country Link
US (3) US9678074B2 (fr)
EP (1) EP2831106B1 (fr)
JP (1) JP6120944B2 (fr)
CN (1) CN104540849B (fr)
AU (1) AU2013240301B2 (fr)
BR (1) BR112014023642A2 (fr)
CA (1) CA2869899C (fr)
WO (1) WO2013148272A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020148720A1 (fr) * 2019-01-17 2020-07-23 University Health Network Fantômes de tissu

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013148272A1 (fr) 2012-03-28 2013-10-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nouvelle protéine interféron-λ4 (ifnl4), molécules d'acide nucléique associées, et leurs utilisations
CN106222178A (zh) * 2016-08-08 2016-12-14 武汉大学 一种重组干扰素λ4编码cDNA序列及其制备方法和应用
JP6948685B2 (ja) * 2016-11-04 2021-10-13 国立大学法人金沢大学 抗癌作用増強剤及び癌治療支援方法
GB201621728D0 (en) 2016-12-20 2017-02-01 Ucb Biopharma Sprl Methods
CN107893087A (zh) * 2017-11-07 2018-04-10 北京康宝利华生物科技有限公司 一种重组猪λ3干扰素的制备方法及其应用
KR20210023737A (ko) * 2019-08-21 2021-03-04 한국과학기술원 신규 인터페론 람다 변이체 및 이의 제조방법
AU2021353585A1 (en) * 2020-10-01 2023-05-18 The Johns Hopkins University Bcg based vaccine compositions and methods of use thereof
CN114920817B (zh) * 2022-05-12 2023-09-05 华中农业大学 一种猪干扰素λ4重组蛋白及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0648334A4 (fr) 1992-07-02 1996-11-20 Quidel Corp Dosages immunologiques au moyen de conjugues enzymatiques colores complexes.
US5424193A (en) 1993-02-25 1995-06-13 Quidel Corporation Assays employing dyed microorganism labels
EP0705426A4 (fr) 1993-06-09 1998-07-08 Quidel Corp Titrages en une etape specifiques d'un antigene
US5415994A (en) 1993-08-02 1995-05-16 Quidel Corporation Lateral flow medical diagnostic assay device with sample extraction means
US5656502A (en) 1995-06-07 1997-08-12 Diagnostic Chemicals Limited Test strip holder and method of use
US6001658A (en) 1996-09-13 1999-12-14 Diagnostic Chemicals Limited Test strip apparatus and method for determining presence of analyte in a fluid sample
GB9817266D0 (en) 1998-08-07 1998-10-07 Imperial College Method
CA2395408A1 (fr) * 1999-12-08 2001-06-04 Amgen, Inc. Molecules de type interferon et utilisations
WO2010025380A2 (fr) * 2008-08-28 2010-03-04 Vertex Pharmaceuticals Incorporated Analyse de génotypes du vhc
CN102459647B (zh) 2009-05-21 2015-05-06 默沙东公司 与干扰素-α应答有关的遗传标记
US20100316608A1 (en) 2009-06-15 2010-12-16 Vijayaprakash Suppiah Method of Determining A Response To Treatment With Immunomodulatory Composition
AU2010277239A1 (en) 2009-07-31 2012-02-02 Centre Hospitalier Universitaire Vaudois Methods for diagnosing or predicting hepatitis C outcome in HCV infected patients
JP5956347B2 (ja) 2009-12-22 2016-07-27 ヤンセン・サイエンシズ・アイルランド・ユーシー ペグインターフェロン及びリバビリンへの反応に関する処置前血清ｉｐ−１０定量と組み合わされたｉｌ２８ｂ遺伝子多型性の予測値は、単独のこれらの生物マーカーのいずれとの比較においても高められる。
EP2726632A1 (fr) 2011-06-30 2014-05-07 Centre Hospitaller Universitaire Vaudois (CHUV) Polymorphismes associés à une absence de réponse à un traitement de l'hépatite c ou à une prédisposition à une clairance non spontanée de l'hépatite c
US20140271542A1 (en) 2011-10-05 2014-09-18 The United States Of America As Represented By The Secretary, Department Of Health And Human Service Genetic marker for predicting prognosis in patients infected with hepatitis c virus
WO2013148272A1 (fr) 2012-03-28 2013-10-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nouvelle protéine interféron-λ4 (ifnl4), molécules d'acide nucléique associées, et leurs utilisations

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020148720A1 (fr) * 2019-01-17 2020-07-23 University Health Network Fantômes de tissu

Also Published As

Publication number Publication date
CN104540849A (zh) 2015-04-22
JP6120944B2 (ja) 2017-04-26
AU2013240301A1 (en) 2014-11-06
WO2013148272A1 (fr) 2013-10-03
WO2013148272A9 (fr) 2014-09-25
EP2831106B1 (fr) 2020-07-15
CA2869899C (fr) 2021-06-22
AU2013240301B2 (en) 2017-10-05
US20150050640A1 (en) 2015-02-19
JP2015514709A (ja) 2015-05-21
BR112014023642A2 (pt) 2017-07-18
US9678074B2 (en) 2017-06-13
EP2831106A1 (fr) 2015-02-04
US10962539B2 (en) 2021-03-30
CN104540849B (zh) 2020-07-28
US20200292546A1 (en) 2020-09-17
US20170254808A1 (en) 2017-09-07

Similar Documents

Publication Publication Date Title
US20200292546A1 (en) A NOVEL INTERFERON-(lambda)4 (IFNL-4) PROTEIN, RELATED NUCLEIC ACID MOLECULES, AND USES THEREOF
JP4969638B2 (ja) 単球由来核酸および関連する組成物ならびに方法
US10927414B2 (en) Methods and kits for determining predisposition to develop kidney diseases
US20220017964A1 (en) Cornulin (CRNN) Variants And Uses Thereof
CN109563516B (zh) Gpr156变体及其用途
CA2534382C (fr) Mutations du gene epm2b associees a la maladie de lafora
US20060183114A1 (en) Novel Eosinophil Cationic Proteins used in the Treatement of Asthematic and Allergic Disorders
JP7237064B2 (ja) 単一免疫グロブリンインターロイキン－１受容体関連（ｓｉｇｉｒｒ）変異型及びその使用
Scherer et al. Lafora's disease gene
AU2002326957B2 (en) Transductin-1 and transductin-2 and applications to hereditary deafness
CN111278851A (zh) 溶质运载体家族14成员1(slc14a1)变体及其用途
WO2002089829A2 (fr) Sequences
Chen Molecular genetic investigation of Shar-Pei fever: a disease similar to human Familial Mediterranean fever
WO2003091277A2 (fr) Haplotypes du gene cetp

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140916